
|Articles|March 1, 2004
Satisfactory response
Washington - Etanercept can be safely administered to AIDS patients with difficult-to-treat inflammatory conditions, according to Robert Wallis, associate professor of medicine at UMDNJ-NJMS, who presented a poster at the February 2004 AAD meeting describing results of a Phase I trial conducted in Kampala, Uganda. "There does not appear to be a substantial risk that either opportunistic infections or HIV disease will be deleteriously affected by this treatment," said Dr. Wallis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
JAK Inhibitors Show Comparable Safety to TNF Antagonists
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















